229 related articles for article (PubMed ID: 30285894)
1. Treatment of pustular psoriasis with anakinra: a statistical analysis plan for stage 1 of an adaptive two-staged randomised placebo-controlled trial.
Cro S; Smith C; Wilson R; Cornelius V
Trials; 2018 Oct; 19(1):534. PubMed ID: 30285894
[TBL] [Abstract][Full Text] [Related]
2. A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial.
Cro S; Patel P; Barker J; Burden DA; Griffiths CEM; Lachmann HJ; Reynolds NJ; Warren RB; Capon F; Smith C; Cornelius V
Trials; 2020 Feb; 21(1):158. PubMed ID: 32041649
[TBL] [Abstract][Full Text] [Related]
3. A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial.
Cornelius V; Wilson R; Cro S; Barker J; Burden D; Griffiths CEM; Lachmann H; McAteer H; Reynolds N; Pink A; Warren RB; Capon F; Smith C
Trials; 2018 Aug; 19(1):465. PubMed ID: 30157880
[TBL] [Abstract][Full Text] [Related]
4. Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT).
Cro S; Cornelius VR; Pink AE; Wilson R; Pushpa-Rajah A; Patel P; Abdul-Wahab A; August S; Azad J; Becher G; Chapman A; Dunnil G; Ferguson AD; Fogo A; Ghaffar SA; Ingram JR; Kavakleiva S; Ladoyanni E; Leman JA; Macbeth AE; Makrygeoegou A; Parslew R; Ryan AJ; Sharma A; Shipman AR; Sinclair C; Wachsmuth R; Woolf RT; Wright A; McAteer H; Barker JNWN; Burden AD; Griffiths CEM; Reynolds NJ; Warren RB; Lachmann HJ; Capon F; Smith CH;
Br J Dermatol; 2021 Aug; 186(2):245-56. PubMed ID: 34411292
[TBL] [Abstract][Full Text] [Related]
5. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis.
Tauber M; Viguier M; Alimova E; Petit A; Lioté F; Smahi A; Bachelez H
Br J Dermatol; 2014 Sep; 171(3):646-9. PubMed ID: 24684162
[TBL] [Abstract][Full Text] [Related]
6. Oral alitretinoin treatment in patients with palmoplantar pustulosis inadequately responding to standard topical treatment: a randomized phase II study.
Reich K; Graff O; Mehta N
Br J Dermatol; 2016 Jun; 174(6):1277-81. PubMed ID: 26800106
[TBL] [Abstract][Full Text] [Related]
7. Response to: 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)': reply from the authors.
Cro S; Smith CH
Br J Dermatol; 2022 May; 186(5):909-910. PubMed ID: 34878650
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
9. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study.
Bissonnette R; Poulin Y; Guenther L; Lynde CW; Bolduc C; Nigen S
J Eur Acad Dermatol Venereol; 2011 Dec; 25(12):1402-8. PubMed ID: 21349113
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial.
Bissonnette R; Nigen S; Langley RG; Lynde CW; Tan J; Fuentes-Duculan J; Krueger JG
J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1298-305. PubMed ID: 24112799
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
Gottlieb A; Sullivan J; van Doorn M; Kubanov A; You R; Parneix A; Hugot S; Milutinovic M
J Am Acad Dermatol; 2017 Jan; 76(1):70-80. PubMed ID: 27707593
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.
Kt S; Thakur V; Narang T; Dogra S; Handa S
Am J Clin Dermatol; 2021 May; 22(3):415-423. PubMed ID: 33712987
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T; Okubo Y; Kobayashi S; Sano S; Morita A; Imafuku S; Tada Y; Abe M; Yaguchi M; Uehara N; Handa T; Tanaka M; Zhang W; Paris M; Murakami M
Am J Clin Dermatol; 2023 Sep; 24(5):837-847. PubMed ID: 37233897
[TBL] [Abstract][Full Text] [Related]
15. A statistical analysis plan for the efficiency and safety of Chinese herbal medicine used concurrently with topical therapy for psoriasis vulgaris.
Lu L; Xuan M; Yan Y; Li G; Zhou L; Wen Z; Lu C
Trials; 2016 Oct; 17(1):482. PubMed ID: 27716422
[TBL] [Abstract][Full Text] [Related]
16. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Moran A; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Greenbaum CJ; Herold KC; Marks JB; Raskin P; Sanda S; Schatz D; Wherrett DK; Wilson DM; Krischer JP; Skyler JS; ; Pickersgill L; de Koning E; Ziegler AG; Böehm B; Badenhoop K; Schloot N; Bak JF; Pozzilli P; Mauricio D; Donath MY; Castaño L; Wägner A; Lervang HH; Perrild H; Mandrup-Poulsen T;
Lancet; 2013 Jun; 381(9881):1905-15. PubMed ID: 23562090
[TBL] [Abstract][Full Text] [Related]
18. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study.
Bhushan M; Burden AD; McElhone K; James R; Vanhoutte FP; Griffiths CE
Br J Dermatol; 2001 Oct; 145(4):546-53. PubMed ID: 11703279
[TBL] [Abstract][Full Text] [Related]
19. Response to 'Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT)'.
Yatsuzuka K; Murakami M
Br J Dermatol; 2022 May; 186(5):908. PubMed ID: 34878653
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
